BACKGROUND The 9th edition of the TNM classification (TNM-9) refines anatomical staging in head and neck cancer, maintaining p16-based categorization for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). However, anatomical extent alone does not capture key biological and host-related determinants of clinical behavior. METHODS In this concept-driven synthesis, we integrate TNM-9 anatomy with evidence on transcriptional viral activity, p16 discordance, nodal morphology including imaging-defined extranodal extension (iENE), immune microenvironment, and host modifiers such as smoking and comorbidity. We propose a layered integrative framework that preserves TNM-9 structure while contextualizing tumor biology. The review is based on a selective synthesis of key translational and clinical studies identified through literature searches and expert knowledge, without a formal systematic approach. RESULTS TNM-9 improves anatomical prognostic stratification at the population level, but identical anatomical stages encompass biologically heterogeneous entities. HPV RNA expression distinguishes biologically favorable tumors from p16+/HPV-inactive disease. iENE retains prognostic relevance in HPV-associated OPSCC, although its radiological appearance may partly reflect immune-associated stromal remodeling and cystic nodal morphology rather than invasive behavior alone. Smoking exposure, comorbidity burden, and immune-related host factors modify survival independent of tumor extent, explaining different outcomes within identical TNM stages. CONCLUSIONS TNM-9 should be interpreted as an anatomical framework supplemented by biological and host factors. A multidimensional understanding enhances clinical applicability, avoids overtreatment of biologically favorable disease and highlights high-risk phenotypes concealed by anatomy alone. This perspective supports precise, biology-informed risk assessment in HPV-associated OPSCC. .
Background Extranodal extension (ENE) is an established adverse prognostic factor in oral cavity squamous cell carcinoma (OCSCC), but the clinical relevance of its extent remains uncertain. This systematic review and meta-analysis evaluated the prognostic impact of quantitatively defined minor versus major ENE, with particular emphasis on the conventional 2-mm threshold. Methods PubMed, Scopus, Embase, and the Cochrane Library were searched from inception to August 2026. Studies of surgically treated OCSCC assessing pathological ENE extent and oncological outcomes were included. Random-effects meta-analyses using restricted maximum likelihood and Hartung-Knapp inference were performed when at least three compatible adjusted hazard ratios (HRs) were available. Risk of bias was assessed using QUIPS. Results Twenty-two reports representing 18 independent cohorts were included. Five studies contributed to the primary overall survival (OS) meta-analysis. Major ENE was associated with significantly worse OS than minor ENE (pooled HR 2.01, 95% CI 1.10–3.66; I2 = 60.5%). Three studies contributed to the disease-free survival (DFS) meta-analysis, showing a concordant but imprecise association (pooled HR 2.16, 95% CI 0.44–10.66; I2 = 59.3%). Alternative thresholds and morphological classifications also generally suggested poorer outcomes with increasing ENE extent. Conclusions ENE extent provides prognostic information beyond binary ENE status in OCSCC. Major ENE is associated with worse OS, while evidence for DFS is directionally consistent but less precise. The 2-mm cutoff should be considered clinically useful but not yet biologically definitive.
PURPOSE We investigated the risk and prognostic value of pre-treatment nodal progression to inform the safe de-escalation of elective nodal irradiation (ENI) in high-risk oropharyngeal squamous cell carcinoma (OPSCC). METHODS We identified patients with p16-negative, clinical T4, node-positive OPSCC treated consecutively with definitive radiotherapy between 2008 and 2021 from a prospectively maintained database. Pre-treatment diagnostic scans were compared against simulation scans to evaluate nodal disease based on pre-specified criteria, growth kinetics, and imaging-detected extranodal extension (iENE). Association of nodal factors and oncologic outcomes were assessed using regression models. RESULTS A total of 79 patients with a median 30-day interval between diagnostic and simulation scan were identified. Nodal growth was minimal with a median absolute change of + 0.5 cc and growth rate of 0.3%/day. Nodal kinetics and duration between imaging were not prognostic for treatment response. While no patients developed de novo pathological nodal disease, 14% of patients had indeterminant nodes on diagnostic scan, with 27% of these becoming pathological at time of simulation. Total nodal volume was highly correlated with presence of iENE, and was prognostic for locoregional failure (HR = 1.02, p = 0.03), distant failure (HR = 1.02, p = 0.02), and progression-free survival (HR = 1.02, p = 0.05). All regional failures were in-field of high dose treatment volumes. CONCLUSIONS Pre-treatment nodal disease volume, but not growth kinetics, was a prognostic factor in locally advanced OPSCC. While lack of new nodal disease and minimal growth over a 30-day pre-treatment interval supports the investigation of novel timing of ENI, particular care should be taken in patients to identify and appropriately manage indeterminate nodes at risk for progression.
